ORLANDO, Fla. and CAMBRIDGE, Mass.--(BUSINESS WIRE)--ARIAD Pharmaceuticals, Inc. (Nasdaq: ARIA) today announced that its next product candidate, AP24534 – a novel kinase inhibitor discovered by ARIAD scientists – has the potential to treat the major clinically relevant genetic variants of chronic myeloid leukemia (CML), the clear unmet medical need in this hematologic cancer. These preclinical results are being presented today at the American Society of Hematology (ASH) 48th Annual Meeting in Orlando, Florida.
